

Review Paper

Clinical Interpretation and Diagnostic Relevance of Hepatitis B Serological Profile Testing

ABSTRACT

Hepatitis B virus infection constitutes a public health menace in many regions of the world. The dynamic nature of the infection and the characteristic variations in the serological markers associated with the various phases of the infection makes its classification, treatment and management a serious challenge to health professionals. Hepatitis B serologic profile is generated from the measurement of several hepatitis B virus specific antigens and antibodies. Immunological responses from the constellation of the assay report can be used to differentiate acute from chronic infection; classify the different phases of the infection; recognise past, resolved and active infection; identify occult and mutant form of the infection. Accurate interpretation of the profile report will abet the diagnosis of hepatitis B virus infection and its associated disease, hence, identifying and linking infected individuals, to appropriate care and treatment services, thereby reducing hepatitis B related mortality and unnecessary expenses on unwarranted medications. This review presents a comprehensive overview of the various forms and the natural history of chronic hepatitis B infection, the serological markers and a guide to the interpretation of various serological patterns associated with hepatitis B virus infection with the sole purpose of providing myriad of relevant information to guide healthcare providers in the diagnosis, treatment and management of those infected with Hepatitis B virus (HBV).

Key words: Chronic Hepatitis B; Hepatitis B envelope antigen negative; Hepatitis B surface antigen; Hepatitis B Virus; Hepatitis B virus DNA; Immunological response; Occult Hepatitis B; Serological Markers

1. INTRODUCTION

Hepatitis B virus (HBV) infection is a major cause of acute and chronic liver disease. It is an infectious disease that leads to a wide spectrum of liver complications, ranging from acute hepatitis including fulminant hepatic failure to chronic hepatitis, decompensated cirrhosis, hepatocellular carcinoma and end-stage liver disease [1]. Despite the existence of an effective vaccine since 1982, the burden of viral hepatitis B continues to constitute a public health threat in many regions of the world, particularly in developing countries [2]. Current reports by the world Health Organization (WHO) estimates that 60% of the world's population live in areas where HBV infection is highly endemic, particularly in Asia and Africa with about 248 million people living with chronic HBV infection (CHB) and an estimated 1.4 million deaths recorded annually resulting from cirrhosis and hepatocellular carcinoma (HCC) [3]. Hepatitis B virus is an enveloped DNA virus that infects the liver and causes hepatocellular necrosis and inflammation [4]. HBV is transmitted predominantly by percutaneous or mucosal exposure to infected blood and body fluids, which includes saliva, menstrual, vaginal and seminal fluids [5]. Perinatal transmission has been identified as the major route of HBV transmission in many parts of the world and a notable factor in sustaining the reservoir of the infection in some regions, particularly in South-East Asia [6-7]. The diagnosis of HBV infection and its associated disease is based on the accurate interpretation of clinical, biochemical, histological, and serologic findings [8]. The WHO guideline on Hepatitis B testing described testing and diagnosis of HBV infection as the entry point to gaining access to prevention, care and treatment services, as well as a crucial component of an effective response to the hepatitis epidemic [3]. HBV testing is done with the following specific objectives; identifying and linking infected individuals, to appropriate care and treatment services; reducing hepatitis B related mortality by providing treatment to those affected; providing link to preventive interventions such as hepatitis B vaccination to reduce transmission; monitoring response to antiviral treatment; surveillance to detect outbreaks; monitor trends in incidence and identifying risk factor; surveillance to estimate the prevalence of chronic infection, monitor trends in sentinel groups and screening in blood transfusion services to prevent transmission via infected blood and its products [3]. Serological assays and nucleic acid testing (NAT) are the screening and diagnostic tool

utilised to detect HBV infectious in many regions of the world. Serological assays are employed as the first line testing strategy due to their relatively low cost compared to NAT. They are based on immunoassay principle and can detect hepatitis B surface antigen (HBsAg) in infected body fluids. NAT technologies are deployed to detect the viraemic state of the infection. They are instrumental in differentiating active from inactive infection, prioritizing those eligible for treatment and signaling when antiviral treatment should be discontinued due to non-response, resistance or to effective suppression of the virus [3]. Complete eradication of HBV is difficult because of its tendency to integrate into the host genome, treatment is however, targeted at sustaining suppression of the HBV DNA levels; normalizing alanine aminotransferase (ALT) levels; delaying or arresting the progression of liver injury and development of cirrhosis and HCC [9]. HBV infection is an intractable pestilence, however, WHO recommends the use of antiviral agents tenofovir and entecavir for treatment of HBV infection. These agents have been shown to effectively suppress HBV replication, prevent progression to cirrhosis, and reduce the risk of HCC and liver-related morbidity and mortality [4,10].

2. VARIOUS FORMS OF HEPATITIS B VIRUS INFECTION

2.1 Acute Hepatitis B Virus Infection

Acute HBV infection is characterized by the presence of HBsAg and immunoglobulin M (IgM) antibody to Hepatitis B core antigen (HBcAg) [5]. The acute form of the infection is usually self-limiting, consequent to the spontaneous clearance of the virus in 90–95% patients within 6 months of infection [8]. Acute infection can however, progress to acute inflammation and hepatocellular necrosis, with a case fatality rate of 0.5–1% [1]. The clinical incubation period of acute hepatitis B infection averages between 2–3 months and can range from 1–6 months after exposure [8].

2.2 Chronic Hepatitis B Virus Infection

CHB infection has a variable and dynamic course and can be defined as the persistent of HBsAg in the blood or serum for longer than six months after an acute infection, with or without associated active viral replication, evidence of hepatocellular injury and inflammation [1]. Worldwide, only 5–10% of patients with acute HBV infection progresses to the chronic state, which is associated with considerable mortality and morbidity [11]. Acquisition of HBV infection at birth or early childhood has been shown to result to chronic condition in about 90% of infected individuals [12].

2.3 Hepatitis B e antigen Negative Chronic Hepatitis B Virus Infection

CHB infection can be broadly categorised into hepatitis B envelope antigen (HBeAg) positive and HBeAg negative chronic HBV infection based on the expression of HBeAg [9]. HBeAg is a biomarker of high levels of HBV replication and infectivity. It is expressed in the active state of acute and chronic HBV infection and it is associated with an increased risk of hepatocellular carcinoma [13-14]. Chronic HBeAg negative infection is the predominant form of CHB infection worldwide [15]. HBeAg-negative CHB infection consists of individuals with varying levels of viral replication and liver disease status [16]. It can be broadly sub-categorized into inactive and active forms. The former can be characterized with a normal ALT levels and low HBV DNA levels without significant necroinflammatory disease. Whereas, the latter group can comprise individuals with chronic necroinflammatory disease of the liver and a naturally occurring mutant form of HBV that does not produce HBeAg because of a mutation in the precore or core promoter region of the HBV genome [17-18]. The predominant form of precore mutation involves a point mutation from G to A at nucleotide 1896 (G1896A), which creates a stop codon that results in loss of HBeAg synthesis. Similarly, the most commonly observed core promoter mutation involves a two-nucleotide substitution at nucleotides 1762 and 1764 [19-20]. Persons with the active form of HBeAg-negative infection have the propensity of developing marked viral reactivation and a tendency of being refractory to antiviral treatment [21]. It is pertinent to identify and closely monitored this group of patients as treatment may be indicated to prevent progression to fibrosis and cirrhosis [16]. HBeAg-negative form of chronic HBV was considered in the context of the various forms of HBV infection in this write up for two obvious reasons. Firstly, a larger proportion of HBV infected individuals are asymptomatic and predominantly HBeAg negative, thus, portending the need for further assessment to differentiate those who are inactive carriers from those harboring the precore or basal core promoter mutants of the virus. Differentiating between these groups of patients will require the use of additional investigations like measuring aminotransferase levels to help

determine liver inflammation, quantification of HBV DNA levels to differentiate active from inactive HBeAg-negative infection and the use of non-invasive diagnostic tests (Transient elastography, aspartate aminotransferase (AST)-to-platelet ratio index (APRI), and fibrosis-4 (FIB-4)) to assess the stages of liver disease (3). However, the accessibility and cost implication of the additional investigations can become a significant impediment to the effective care and management of people with CHB. Secondly, CHB is a heterogeneous disease with a dynamic natural history. Serological markers fluctuate as the infection transcends through the various phases of the natural course of the disease. Continuous monitoring of HBV DNA and other markers in both the active and inactive form of the disease is of paramount necessity in identifying disease progression and when to initiate therapy. However, proper classification of the disease, the precise correlation of laboratory results with clinical findings and the cost implication of the repeated assays might also be a hindrance in the proper care and management of people with CHB.

2.4 Occult or Latent Hepatitis B Virus Infection

Occult or latent HBV infection (OBI) is a persistent form of HBV infection, characterized by the absence or undetected HBsAg in the serum [22-24]. It can be categorised as either seropositive or seronegative OBI. Seropositive OBI occurs when serum HBV DNA is detectable and both hepatitis B core antibody (anti-HBc)/hepatitis B surface antibody (anti-HBs)IgGs antibodies are positive or only anti-HBcIgG is positive. Seronegative OBI on the other hand is evident by the detection of only HBV DNA in serum/or liver tissue without the corresponding detection of anti-HBc IgG and or anti-HBs IgG antibodies [25]. The reduced expression of HBV surface proteins and the low binding affinity of monoclonal antibody against HBsAg in OBI cases have been attributed to various forms of mutations in the HBsAg gene [26-27]. HBV Genotypes A, C, G, E and D have been found among patients with OBI in different regions of the world. The predominant form is usually region specific [25]. OBI is of clinic relevance and a public health concern due to the risk of reactivation it poses to individuals with previous history of HBV infection along with patients co-infected with hepatitis C virus/human immunodeficiency virus and patients undergoing chemotherapy. These patients are at risk of developing liver cirrhosis and HCC [22-24]. Furthermore, recipients of blood donation and organ transplant are also at risk of acquiring OBI, thus, necessitating the advocacy for a highly sensitive molecular means in screening of HBV DNA in blood and organ donors [28,29].

3. NATURAL HISTORY OF CHRONIC HEPATITIS B

The various liver pathologies associated with CHB are the cumulative effect of the interplay between the host defense system and HBV activities. The clinical presentations manifest as the infection progresses through the natural course of the disease. The natural history of CHB can be divided into 4 phases: The natural course of CHB begins with immune tolerant phase. This phase is observed primarily in perinatally acquired infection and individuals in this phase are positive for HBeAg with elevated levels of HBV DNA>20,000 IU/mL but have a normal serum ALT level. Liver biopsy usually shows no or minimal histological changes [16, 31]. The increased viral activity during this period can be attributed to the role played by HBeAg, acting as an immune tolerant protein, thus, aiding the virus to evade the immune system [31]. Immune clearance phase, also known as immune active phase is the next phase in the natural history of CHB infection. It is the phase where the host's immune system recognizes and responds to the invading HBV pathogen thus leading to the damage of hepatocyte [32]. This phase is characterized with an elevated ALT level and decreased HBV DNA level. HBeAg may be cleared with seroconversion to anti-HBeAg but may still persist in some individuals [33]. Protracted immune clearance phase may increase the risk of liver fibrosis and therefore disease progression [34]. Immune response to HBV leads to the suppression of HBV DNA, normalization of ALT and subsequent seroconversion of HBeAg to anti-HBe antibody. This low replicative phase is known as the inactive carrier state or the immune control state of the disease [35-36]. Inactive phase of the disease depicts a state with low risk of liver disease progression and has a good prognosis [37]. Patients in the inactive carrier state constitute the largest group of persons with chronic HBV infection. Although, they are usually asymptomatic with low or no virological activities occurring at the stage, however, spontaneous reactivation might be observed in approximately 20%-30% of the inactive HBsAg carriers and some may revert to a phase of significant viraemia with fluctuating ALT. Multiple episodes of reactivation or a sustained reactivation can cause progressive liver damage [38]. In addition to the risk of reactivation and the emergence of mutant viruses that fail to express HBeAg, inactive HBsAg carrier state can also be associated with a number of other potential outcomes, which includes; indefinite persistence of the inactive carrier status, resolution of chronic infection (evident by HBsAg clearance and appearance of anti-HBsAg antibody and reactivation of the disease due to

recrudescence of the original infection [39-41]. The reactivated phase is the fourth phase in the natural history of CHB infection, those arising as a result of mutations in the precore or core promoter region of the HBV give rise to HBeAg negative CHB disease (HBeAg⁻CHB). Individual in this phase react negative to HBeAg, with or without seroconversion to anti-HBeAg, HBV DNA can be detected, serum ALT level fluctuates and liver biopsy usually shows active inflammation [39,42]. However, not all patients go through each of the four phases [30]. Serological markers that aid in differentiating these phases are depicted in table 1.

4. SEROLOGICAL MARKERS OF HEPATITIS B VIRUS INFECTIONS

4.1 Hepatitis B Surface Antigen (HBsAg)

HBsAg also known as the Australian antigen is the first serological marker of HBV infection to appear. The window period between HBV infection and detection of HBsAg is estimated to be around 38 days; however, this depends on other factors such as the analytical sensitivity of assay used, the immunocompetence of the host, individual virus kinetics and occult HBV type of infection where HBsAg is undetected [3]. HBsAg level varies throughout the different phases of CHB infection and across different HBV genotypes [43-44]. Quantification and monitoring of HBsAg level has been identified as a potential alternative marker for assessing HBV viraemia and response to antiviral treatment [3]. Quantification of HBsAg can also be utilised to differentiate active from inactive disease among HBeAg-negative individuals and to predict disease reactivation in asymptomatic HBeAg-negative patient [45-46].

4.2 Hepatitis B Surface Antibody (Anti-HBs)

Anti-HBs is a neutralizing antibody that confers protective immunity against HBV infection. It is produced during the window period of HBV infection, after the spontaneous clearance of HBsAg or following immunization with HBsAg vaccine preparations [3]. Anti-HBs can be used to monitor post-immunization responses. In this case, anti-HBs appears in the absence of anti-HBc. However, anti-HBs can coexist with anti-HBc in patients with resolved HBV infection. Anti-HBs can also be detected in patients with reactive HBsAg. Its presence in this scenario cannot be used to exclude current infection [47].

4.3 Hepatitis B envelope Antigen (HBeAg)

HBeAg is a secreted, immunologically soluble antigen that is associated with high levels of HBV replication and progressive liver disease. The presence of HBeAg is a marker of high infectivity and it's useful in deciding when to commence and stop antiviral therapy [48].

4.4 Hepatitis B envelope Antibody (Anti-HBe)

Anti-HBe is a neutralizing antibody that emerges during HBeAg seroconversion. The detection of Anti-HBe in the serum is associated with clinical improvement of hepatitis which includes; reduced HBV DNA, indicating decreased viral replication and infectivity, normalized serum aminotransferase levels, and quiescence of inflammation in the liver usually indicating decreased viral replication and infectivity [49]. Anti-HBe is usually detected in the immune-control and immune-escape phases of the natural course of chronic HBV infection. It may also be detected at the end of immune-tolerance phase when it coexist with HBeAg during the period of seroconversion from envelop antigen to envelop antibody [50,51].

4.5 Hepatitis B core Antibody (Anti-HBc)

Anti-HBc are non neutralizing antibodies directed against HBV core (capsid) protein. Anti-HBc IgM antibodies are expressed during acute HBV infection but may remain detectable for up to 6 months. Detecting Anti-HBc IgM is diagnostic, as it can be used to differentiate between acute and chronic HBV infection. However, its reappearance during "flares" in chronic HBV infection makes it an unreliable indicator of recent primary HBV infection [3]. Commercially diagnostic assays detect anti-HBc total antibodies (Anti-HBc (total)) which comprises both IgM and IgG antibodies. Anti-HBc (total) is the most constant marker of HBV infection and when it appears together with anti-HBs, it indicates resolved infection. However, the presence of anti-HBc in the absence of HBsAg and anti-HBs is defined as "isolated anti-HBc" or "anti-HBc alone" and the serological response is compatible with

acute, resolved, and chronic HBV infection but might also represent occult HBV infection or infection with atypical variant strains of HBV [52, 53,54]. The routine screening of blood donors for anti-HBc has been implemented in many countries [52, 55]. This is attributed to the recognized fact that anti-HBc may be the only detectable serological marker of HBV infection in blood donors with resolved infection, low grade chronic infection or infection with atypical variant strains of HBV [56-58]

4.6 Hepatitis B Virus DNA (HBV DNA)

HBV is an envelope virus with a partially double stranded, circular DNA. The full length DNA strand is about 3020–3320 nucleotides long, while the short length strand is about 1700–2800 nucleotides long [59]. HBV viral genomes can be detected and quantified in serum using nucleic acid testing technologies (NAT). The measured HBV DNA which is also called HBV viral load is expressed in international units per milliliter (IU/mL) as the recognized international standard. It can also be expressed in copies/ml. conversion between IU/mL and copies/ml is possible using the formular; 1 IU/mL = 5.3 copies/mL [3]. High level of HBV DNA, can range from tens of thousands to billions, and it is a direct and accurate measure of active HBV viral replication, which correlates with disease progression and a marker of infectivity [57]. Moderate amount of HBV DNA however, drifts around 10,000 IU/mL while low or undetectable levels are less than 2,000 IU/mL which indicate “inactive” infection [60]. Measurement of HBV DNA can be used to diagnose early HBV infection before the appearance HBsAg. Similarly, HBV DNA estimation can be used to differentiate active from inactive HBeAg-negative infection, and in conjunction with ALT levels and degree of liver fibrosis it can be used to determine the need for antiviral therapy [61]. HBV viral load is pivotal in deciding and selecting HBV infected candidates eligible for antiviral therapy, consequently, it can be used in monitoring treatment response. Elevated values while on treatment may indicate inadequate adherence or the emergence of res istant variants [62, 63,64]. HBV DNA detection is also a useful marker in diagnosing HBV occult infection [65, 66].

Table 1: Differentiating Chronic Hepatitis B Phases using Hepatitis BVirus Serological Markers

CHB Phase	ALT	HBsAg	Anti-HBs	HBeAg	Anti-HBe	Anti-HBc	HBV DNA (UI/ml)
Immune tolerance	Persistently normal	Reactive	Non-Reactive	Reactive	Non-Reactive	Reactive	>20,000 IU/mL
Immune clearance	Persistently elevated	Reactive	Non-Reactive	Reactive	Non-Reactive ^a	Reactive	>20,000 IU/mL or <20,000 IU/mL
Inactive or carrier state	Usually Normal; Characterized occasionally with periodic flares	Reactive	Non-Reactive	Non-Reactive	Reactive	Reactive	<20,000 IU/mL
	Characterized with Periodic flares						
Reactivation	(Persistently or intermittently						
(HBeAg⁻ CHB)	Abnormal)	Reactive	Non-Reactive	Non-Reactive	Reactive	Reactive	>20,000 IU/mL or <20,000 IU/mL

CHB: Chronic Hepatitis B; ALT: Alanine aminotransferase; HBsAg: Hepatis B surface antigen; Anti-HBs: Hepatitis B surface antibody; HBeAg: Hepatitis B e Antigen; Anti-HBe: Hepatitis B e antibody; Anti-HBc: Hepatitis B core antibody; HBV DNA: Hepatitis B virus DNA; HBeAg⁻ CHB: Hepatitis B e antigen negative chronic hepatitis B. ^aAnti-HBe may coexist with HBeAg at the end of immune-tolerance phase during the period of seroconversion from e antigen to e antibody.

Table 2: A Guide to the Interpretation of various Hepatitis B virus Serological Patterns

HBsAg	Anti-HBs	HBeAg	Anti-HBe	Anti-HBc	Interpretation
Reactive	Non-Reactive	Reactive	Non-Reactive	Reactive	This is compatible with an acute or chronic active HBV infection, with ongoing viral replication. Anti-HBcIgM antibodies can be used to differentiate active from chronic infection. More so, persistence of HBsAg in the serum for more than six months is diagnostic of HBV chronic infection.
Reactive	Non-Reactive	Non-Reactive	Reactive	Reactive	These serological responses are compatible with HBV carrier status / inactive state, or HBeAg ⁺ CHB disease arising as a result of mutation in the precore or core promoter region of HBV. Both presentations can be differentiated using additional HBV markers such as those that assess the stages of liver disease such as ALT, liver histology, APRI score, transient elastography (Fibroscan) and HBV DNA which is a more direct and accurate measurement of active HBV viral replication, which correlates with disease progression.
Reactive	Non-Reactive	Non-Reactive	Non-Reactive	Reactive	
Non-Reactive	Non-Reactive	Non-Reactive	Non-Reactive	Reactive	This immunological response is referred to as "isolated anti-HBc" or "anti-HBc alone." It is compatible with any of the following; acute HBV infection during the window period, resolved HBV infection, CHB infection and occult HBV infection. It can also be attributed to a false positive reaction. Unraveling the clinical status of individuals with isolated anti-HBc requires further investigations such as HBV DNA and anti-HBs measurement. Hepatitis B vaccination of individuals with isolated anti-HBc to measure anti-HBc response has been employed to distinguish the various outcomes associated with isolated anti-HBc. This is based on the premise that those with previous exposure to HBsAg will show an anamnestic anti-HBs response after a single dose of vaccine. The identification of isolated anti-HBc is significant in organ transplant donors and in candidate patients for chemotherapy and immunosuppressive therapy due to the risk of HBV reactivation.
Non-Reactive	Reactive	Non-Reactive	Non-Reactive	Reactive	These serological responses are compatible with resolved or past HBV infection. The presence of Anti-HBc in both episodes indicates past exposure to the virus.
Non-Reactive	Reactive	Non-Reactive	Reactive	Reactive	
Non-Reactive	Reactive	Non-Reactive	Non-Reactive	Non-Reactive	This immunological pattern is compatible with serological response associated with hepatitis B vaccination. The absence of anti-HBc indicates the non existence of ongoing HBV infection or previous exposure to HBV.

241 *HBsAg: Hepatitis B surface antigen; Anti-HBs: Hepatitis B surface antibody; HBeAg: Hepatitis B envelope Antigen; Anti-*
242 *HBe: Hepatitis B envelope antibody; Anti-HBc: Hepatitis B core antibody; HBV DNA: Hepatitis B virus DNA; HBeAg⁺ CHB;*
243 *Hepatitis B e antigen negative, chronic hepatitis B; CHB: Chronic Hepatitis B; ALT: Alanine aminotransferase; HBV: Hepatitis B*
244 *virus; APRI: Aspartate aminotransferase-to-platelet ratio index; TE: Transient elastography;*

245

246 5. CONCLUSION

247 Considering the dynamic nature of HBV infection and the variations associated with the
248 immunological responses in the various phases of the infection, proper classification of the disease
249 and the precise correlation of laboratory results with clinical findings is vital in identifying and linking
250 infected individuals, to appropriate care and treatment services.

251

REFERENCES

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepat.* 2004;11(2):97–107
2. World health organization fact sheet on Hepatitis B. Accessed 6 February 2018. Available:<http://www.who.int>mediacentre>factsheets accessed 6 February 2018>).
3. World health organization (2017). Guidelines on Hepatitis B and C testing. Accessed 6 February 2018. Available: <http://www.who.int/hepatitis/.../guidelines>.
4. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015. Accessed February 2018. Available:(http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1
5. Colin WS, Edgar PS, Lyn F, Anthony EF, Beth PB. Hepatitis B Virus Infection: Epidemiology and Vaccination. *Epidemiological Review.* 2006;28:112–125
6. Yi P, Chen R, Huang Y, Zhou RR, Fan XG. Management of mother-to-child transmission of hepatitis B virus: propositions and challenges. *Journal of Clinical Virology.* 2016;77:32–90.
7. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chan CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatology International.* 2016;10(1):1–98
8. Liang TJ. Hepatitis B: The Virus and Disease. *Hepatology.* 2009; 49(5 Suppl): S13–S21.
9. Nripen S, Rupjyoti T, Subhasish M, Sudeep K, Rakesh T. Management of patients with HBeAg-negative chronic hepatitis B. *Postgraduate Medical Journal.*2007;83:32–39
10. Hadziyannis SJ. Update on hepatitis B virus infection: focus on treatment. *Journal of Clinical and Translational Hepatology.* 2014;2(4):285–91
11. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. *Gastroenterology.* 1992;103:1630–1635
12. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sancheztapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B.*Hepatolog.*1995;21:77–82
13. You S-L, Yang H-I, Chen C-J. Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. *Annals of Medicine* 2004;36:215-24.
14. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY et al.; Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. *N Engl J Med.* 2002;347:168-74
15. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. *J Viral Hepat.* 2002; 9: 52-61
16. Ahmad NA, Soek-Siam T, Rosmawati M. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. *World J Gastroenterol.* 2014 14;20(34): 12045-12055

- 292 17. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a
293 workshop. *Gastroenterology*. 2001; 120: 1828-1853 [PMID: 11375963]
- 294 18. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary
295 of a clinical research workshop. *Hepatology*. 2007; 45: 1056-1075
296 [PMID:17393513DOI: 10.1002/hep.21627]
- 297 19. Merican I, Guan R, Amarapuka D, Chutaputti A, Chien RN, Hasnain SS et al. Chronic
298 hepatitis B virus infection in Asian countries. *J Gastroenterol Hepatol*. 2000;15:135.
- 299 20. Bortolotti F, Cadrobbi P, Crivellaro C, Guido M, Rugge M, Noventa F et al. Long-term
300 outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in
301 childhood. *Gastroenterology* 1990;99:805-10
- 302 21. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant
303 chronic hepatitis B. *J Viral Hepat*. 2001;8:311-21
- 304 22. Ocana S, Casas ML, Buhigas I, Lledo JL. Diagnostic strategy for occult hepatitis B virus
305 infection. *World J Gastroenterol*. 2011;17(12):1553-7.
- 306 23. Liang TJ, Blum HE, Wands JR. Characterization and biological properties of a hepatitis B
307 isolated from a patient without HBV serologic markers. *Hepatology*. 1990;12:204-212.
- 308 24. Rehmann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades
309 after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic
310 T-lymphocyte response. *Nat Med*. 1996;2:1104-1108.
- 311 25. Manoochehr M. Update on occult hepatitis B virus infection. *World J Gastroenterol*. 2016;
312 22(39): 8720-8734
- 313 26. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation
314 of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg
315 ELISA. *Lancet*. 1995; 345:1406-1407 [PMID:7539089 DOI: 10.1016/S0140-6736(95)92599-6]
- 316 27. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus
317 infection in chronic liver disease: full-length genome and analysis of mutant surface
318 promoter. *Gastroenterology*. 2004; 127: 1356-1371 [PMID: 15521005 DOI:
319 10.1053/j.gastro.2004.08.003]
- 320 28. Raimondo G, Pollicino T, Romanò L, Zanetti AR. A 2010 update on occult hepatitis B
321 infection. *Pathol Biol (Paris)* 2010; 58: 254-257 [PMID: 20303674 DOI:
322 10.1016/j.patbio.2010.02.003]
- 323 29. Kim H, Lee SA, Kim DW, Lee SH, Kim BJ. Naturally occurring mutations in large surface
324 genes related to occult infection of hepatitis B virus genotype C. *PLoS One* 2013; 8: e54486
325 [PMID: 3349904 DOI: 10.1371/journal.pone.0054486]
- 326 30. Yim, HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981
327 and what we know in 2005. *Hepatology*. 2006. 43:S173-S181
- 328 31. Brian JM. The Natural History of Chronic Hepatitis B Virus Infection. *Hepatology*. 2009; 49 (5)
329 Suppl.S45-S55
- 330 32. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis
331 B virus therapy. *J Gastroenterol Hepatol*. 2003; 18: 246-252

- 332 33. McMahon BJ. Epidemiology and natural history of hepatitis B. *Semin Liver Dis.*
333 2005;25(Suppl 1):3-8.
- 334 34. Liaw YF, Chu CM. Hepatitis B virus infection. *Lancet.* 2009; 373: 582-592 [PMID: 19217993
335 DOI: 10.1016/S0140-6736(09)60207-5]
- 336 35. de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al. The natural
337 history of asymptomatic hepatitis B surface antigen carriers. *Ann Intern Med* 1993;118:191-
338 194.
- 339 36. Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, et al. Serum
340 hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. *J Hepatol*
341 2002;36:543-546
- 342 37. Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, Serra A, Saracco G,
343 Verme G, Will H. Wild type and e antigen-minus hepatitis B viruses and course of chronic
344 hepatitis. *Proc Natl Acad Sci USA.* 1991; 88: 4186-4190
- 345 38. Ying-Hui S, Chang-He S. Molecular characteristics and stages of chronic hepatitis B virus
346 infection. *World J Gastroenterol.* 2009; 15(25): 3099-3105
- 347 39. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF. Long-term outcome
348 after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. *Hepatology.*
349 2002; **35**:1522–1527.
- 350 40. McMahon, BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536
351 Alaska natives chronically infected with hepatitis B virus. *Ann. Intern. Med.* 2001; 135:759–
352 768
- 353 41. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B.
354 *Hepatology.* 2001; 34: 617-624 [PMID: 11584355 DOI: 10.1053/jhep.2001.27834]
- 355 42. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, et al.. Hepatitis B
356 surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.
357 *J Hepatol* 2010; 52: 508-513 [PMID: 20206400]
- 358 43. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et.
359 Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus
360 (HBV)-infection: a European perspective. *J Hepatol.* 2010; 52: 514-522
- 361 44. Park H, Lee JM, Seo JH, Kim HS, Ahn SH, Kim do Y, et al. Predictive value of HBsAg
362 quantification for determining the clinical course of genotype C HBeAg-negative carriers. *Liver*
363 *Int.* 2012; 32: 796-802
- 364 45. Martinot-Peignoux M, Lapalus M, Laouénan C, Lada O, Netto-Cardoso AC, Boyer N, et al..
365 Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic
366 hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. *J Clin*
367 *Virol.* 2013; 58: 401-407
- 368 46. Deniser Z, Robert Gurdak, GG, Forrest LT, David EN. Loss of Antibody to Surface Antigen.
369 *Am J Clin Pathol.* 1987;88: 229-231.
- 370 47. Mindie HN, Emmet B. K. Are Hepatitis B e Antigen (HBeAg)–Positive Chronic Hepatitis B
371 and HBeAg-Negative Chronic Hepatitis B Distinct Diseases? *Clinical Infectious Diseases.*
372 2008. 47 (10) : 1312–1314

- 373 48. Bortolotti, F, Cadrobbi P, Crivellaro C, Guido M, Rugge M, Noventa F, et al. Long-term
374 outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in
375 childhood. *Gastroenterology*. 1990. 99:805–810
- 376 49. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536
377 Alaska natives chronically infected with hepatitis B virus. *Ann. Intern. Med.* 2001. 135:759–768
- 378 50. Gianluca G, Samanta B, Paolo B, Mosè F, Claudio G, Sara V, et al. Significance of anti-HBc
379 only in blood donors: a serological and virological study after hepatitis B vaccination. *Blood*
380 *Transfusion*. 2014. 12; Suppl 1: s63-8
- 381 51. Kleinman S, Kuhns M, Todd D, Glynn SA, McNamara A, Busch MP et al. Frequency of HBV
382 DNA detection in US blood donors testing positive for the presence of anti-HBc: implications
383 for transfusion transmission and donor screening. *Transfusion* 2003; 43: 696-704.
- 384 52. Qixia W, Paul K, Nasser S. Significance of anti-HBc alone serological status in clinical
385 practice. *The lancet Gastroenterology & Hepatology*. 2017. 2 (2) 123–134
- 386 53. Ramia S, Ramalawi F, Kanaan M, et al. Frequency and significance of antibodies against
387 hepatitis B core antigen as the only serological markers for hepatitis B infection in Lebanese
388 blood donors. *Epidemiol Infect* 2005; 133: 695-9.
- 389 54. Ramia S, Ramalawi F, Kanaan M, Klayme S, Naman R. Frequency and significance of
390 antibodies against hepatitis B core antigen as the only serological markers for hepatitis B
391 infection in Lebanese blood donors. *Epidemiol Infect*. 2005; 133: 695-9
- 392 55. Katsurada A, Marusawa H, Uemoto S, Kaburagi A, Tanaka K, Chiba T. Circulating antibody to
393 hepatitis B core antigen not always reflects the latent hepatitis B virus infection in the liver
394 tissue. *Hepatol Res*. 2003; 25: 105-14
- 395 56. Kay A, Zoulim F (2007). Hepatitis B virus genetic variability and evolution. *Virus Res*. 127 (2):
396 164–76
- 397 57. Alexandra V. Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B.
398 *Clinical Microbiology Reviews*. 2007. 20 (3): 426–439
- 399 58. Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S. et al .2002.
400 Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. *J.*
401 *Hepatol.*36:543–546.
- 402 59. Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C,
403 Hadziyannis SJ. 2003. Significance of hepatitis B viremia levels determined by a
404 quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative
405 chronic hepatitis B virus infection. *Am. J. Gastroenterol*. 98:2261–2267.
- 406 60. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER et al. A treatment
407 algorithm for the management of chronic hepatitis B virus infection in the United
408 States: an update. *Clin. Gastroenterol. Hepatol*. 2006; 4:936–962
- 409 61. Liaw, YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G et al.. Asian-Pacific
410 consensus statement on the management of chronic hepatitis B: a 2005 update. *Liver Int*.
411 2005; 25:472–489
- 412 62. Maria B, Francisco S, Montserrat C, Rosendo J, Francisco R, Rafael E et al. Quantitative
413 Hepatitis B Virus DNA Testing for the Early Prediction of the Maintenance of Response during

- 414 Lamivudine Therapy in Patients with Chronic Hepatitis B. The Journal of Infectious Diseases
415 2001; 183:1277–80
- 416 63. Conjeevaram, HS, Lok AS.. Occult hepatitis B virus infection: a hidden menace? Hepatology.
417 2001; 34:204–206
- 418 64. Torbenson, M, Thomas DL. Occult hepatitis B. Lancet Infect. Dis. 20022:479–486
- 419 65. Catherine MN, John SL, Natural history of chronic hepatitis B: Phases in a complex
420 relationship. World J Gastroenterol. 2014; 20(30): 10395-10404